Evaluation of new iodinated acridine derivatives for targeted radionuclide therapy of melanoma using 125I, an Auger electron emitter

Investigational New Drugs

Volumn 29, Issue 6, 2011, Pages 1253-1263

  Gardette, Maryline ^a,b,c   Papon, Janine ^a,b,c   Bonnet, Mathilde ^a,b,c   Desbois, Nicolas ^d   Labarre, Pierre ^a,b,c   Wu, Ting Dee ^a,e   Miot Noirault, Elisabeth ^a,b,c   Madelmont, Jean Claude ^a,b,c   Guerquin Kern, Jean Luc ^a,e   Chezal, Jean Michel ^a,b,c   Moins, Nicole ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ CLERMONT AUVERGNE   (France)

^c CENTRE JEAN PERRIN   (France)

^d UNIVERSITÉ DE BOURGOGNE   (France)

^e INSTITUT CURIE   (France)

Author keywords

Acridine; Auger electron; Melanoma; Targeted radionuclide therapy

Indexed keywords

ACRIDINE DERIVATIVE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CYTOTOXIC AGENT; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); ICF 01035; ICF 01040; IODINE 125; MELANIN; N (2 DIMETHYLAMINOETHYL) 4 ACRIDINECARBOXAMIDE; UNCLASSIFIED DRUG; INTERCALATING AGENT; RADIOACTIVE IODINE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CELL NUCLEUS MEMBRANE; CELL TRANSPORT; CELL VIABILITY; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG STRUCTURE; ENZYME INHIBITION; IN VITRO STUDY; ISOTOPE LABELING; MASS SPECTROMETRY; MELANOMA; MELANOMA CELL; MELANOSOME; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOIODINATION; RADIOISOTOPE THERAPY; ANIMAL; C57BL MOUSE; CELL NUCLEUS; CHEMISTRY; COMPARATIVE STUDY; ELECTRON; EXPERIMENTAL MELANOMA; METABOLISM;

ACRIDINES; ANIMALS; CELL NUCLEUS; ELECTRONS; INTERCALATING AGENTS; IODINE RADIOISOTOPES; MELANINS; MELANOMA, EXPERIMENTAL; MELANOSOMES; MICE; MICE, INBRED C57BL;

EID: 84856060113     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9471-x     Document Type: Article

References (44)

1. Jennings L, Murphy GM (2009) Predicting outcome in melanoma: where are we now? Br J Dermatol 161:496-503
2. Garbe C, Eigentler TK (2007) Diagnosis and treatment of cutaneous melanoma: state of the art 2006. Melanoma Res 17:117-127 (Pubitemid 46673905)
3. Agarwala SS, Becker JC, Eggermont AM, Flaherty KT, Garbe C, Goldstein AM, Halpern A, Kashani-Sabet M, Hauschild A, Kirkwood JM et al (2009) Meeting report: consensus from the first and second Global Workshops in Melanoma November 19-20, 2008. Pigment Cell Melanoma Res 22:532-543
4. Helmbach H, Rossmann E, Kern MA, Schadendorf D (2001) Drug-resistance in human melanoma. Int J Cancer 93:617-622 (Pubitemid 32695107)
5. Lui P, Cashin R, Machado M, Hemels M, Corey-Lisle PK, Einarson TR (2007) Treatments for metastatic melanoma: synthesis of evidence from randomized trials. Cancer Treat Rev 33:665-680 (Pubitemid 350082665)
6. Olivier KR, Schild SE, Morris CG, Brown PD, Markovic SN (2007) A higher radiotherapy dose is associated with more durable palliation and longer survival in patients with metastatic melanoma. Cancer 110:1791-1795 (Pubitemid 47557304)
7. Rizvi SM, Qu CF, Song YJ, Raja C, Allen BJ (2005) In vivo studies of pharmacokinetics and efficacy of Bismuth-213 labeled antimelanoma monoclonal antibody 9.2.27. Cancer Biol Ther 4:763-768 (Pubitemid 41351177)
8. Dadachova E, Revskaya E, Sesay MA, Damania H, Boucher R, Sellers RS, Howell RC, Burns L, Thornton GB, Natarajan A et al (2008) Pre-clinical evaluation and efficacy studies of a melaninbinding IgM antibody labeled with 188Re against experimental human metastatic melanoma in nude mice. Cancer Biol Ther 7:1116-1127
9. Miao Y, Owen NK, Whitener D, Gallazzi F, Hoffman TJ, Quinn TP (2002) In vivo evaluation of 188Re-labeled alpha-melanocyte stimulating hormone peptide analogs for melanoma therapy. Int J Cancer 101:480-487
10. Miao Y, Owen NK, Fisher DR, Hoffman TJ, Quinn TP (2005) Therapeutic efficacy of a 188Re-labeled alpha-melanocytestimulating hormone peptide analog in murine and human melanoma-bearing mouse models. J Nucl Med 46:121-129 (Pubitemid 43086006)
11. Miao Y, Shelton T, Quinn TP (2007) Therapeutic efficacy of a 177Lu-labeled DOTA conjugated alpha-melanocyte-stimulating hormone peptide in a murine melanoma-bearing mouse model. Cancer Biother Radiopharm 22:333-341 (Pubitemid 47067891)
12. Link EM (1999) Targeting melanoma with 211At/131I-methylene blue: preclinical and clinical experience. Hybridoma 18:77-82 (Pubitemid 29140425)
13. Eisenhut M, Hull WE, Mohammed A, Mier W, Lay D, Just W, Gorgas K, Lehmann WD, Haberkorn U (2000) Radioiodinated N-(2-diethylaminoethyl) benzamide derivatives with high melanoma uptake: structure-affinity relationships, metabolic fate, and intracellular localization. J Med Chem 43:3913-3922
14. Moins N, D'Incan M, Bonafous J, Bacin F, Labarre P, Moreau MF, Mestas D, Noirault E, Chossat F, Berthommier E et al (2002) 123I-N-(2-diethylaminoethyl)- 2-iodobenzamide: a potential imaging agent for cutaneous melanoma staging. Eur J Nucl Med Mol Imaging 29:1478-1484 (Pubitemid 35232050)
15. Edreira MM, Pozzi OR (2006) Iodide benzamides for the in-vivo detection of melanoma and metastases. Melanoma Res 16:37-43 (Pubitemid 44133049)
16. Pham TQ, Greguric I, Liu X, Berghofer P, Ballantyne P, Chapman J, Mattner F, Dikic B, Jackson T, Loc'h C et al (2007) Synthesis and evaluation of novel radioiodinated benzamides for malignant melanoma. J Med Chem 50:3561-3572 (Pubitemid 47195463)
17. Michelot JM, Moreau MF, Veyre AJ, Bonafous JF, Bacin FJ, Madelmont JC, Bussiere F, Souteyrand PA, Mauclaire LP, Chossat FM et al (1993) Phase II scintigraphic clinical trial of malignant melanoma and metastases with iodine-123-N-(2-diethylaminoethyl 4-iodobenzamide). J Nucl Med 34:1260-1266 (Pubitemid 23230353)
18. Chezal JM, Papon J, Labarre P, Lartigue C, Galmier MJ, Decombat C, Chavignon O, Maublant J, Teulade JC, Madelmont JC et al (2008) Evaluation of radiolabeled (hetero) aromatic analogues of N-(2-diethylaminoethyl)-4- iodobenzamide for imaging and targeted radionuclide therapy of melanoma. J Med Chem 51:3133-3144 (Pubitemid 351821874)
19. Bonnet-Duquennoy M, Papon J, Mishellany F, Labarre P, Guerquin-Kern JL, Wu TD, Gardette M, Maublant J, Penault-Llorca F, Miot-Noirault E et al (2009) Targeted radionuclide therapy of melanoma: anti-tumoural efficacy studies of a new 131I-labelled potential agent. Int J Cancer 125:708-716
20. Kassis AI, Adelstein SJ (2005) Radiobiologic principles in radionuclide therapy. J Nucl Med 46(Suppl 1):4S-12S (Pubitemid 47619013)
21. Barendswaard EC, Humm JL, O'Donoghue JA, Sgouros G, Finn RD, Scott AM, Larson SM, Welt S (2001) Relative therapeutic efficacy of (125) I-and (131) I-labeled monoclonal antibody A33 in a human colon cancer xenograft. J Nucl Med 42:1251-1256 (Pubitemid 32717846)
22. Ickenstein LM, Edwards K, Sjoberg S, Carlsson J, Gedda L (2006) A novel 125I-labeled daunorubicin derivative for radionuclide-based cancer therapy. Nucl Med Biol 33:773-783 (Pubitemid 44247737)
23. Kassis AI, Sastry KS, Adelstein SJ (1987) Kinetics of uptake, retention, and radiotoxicity of 125IUdR in mammalian cells: implications of localized energy deposition by Auger processes. Radiat Res 109:78-89 (Pubitemid 17026116)
24. Buchegger F, Perillo-Adamer F, Dupertuis YM, Delaloye AB (2006) Auger radiation targeted into DNA: a therapy perspective. Eur J Nucl Med Mol Imaging 33:1352-1363 (Pubitemid 44630792)
25. Ghirmai S, Mume E, Tolmachev V, Sjoberg S (2005) Synthesis and radioiodination of some daunorubicin and doxorubicin derivatives. Carbohydr Res 340:15-24 (Pubitemid 40023293)
26. Karagiannis TC, Lobachevsky PN, Martin RF (2000) Cytotoxicity of an 125I-labelled DNA ligand. Acta Oncologica (Stockholm, Sweden) 39:681-685
27. Belmont P, Bosson J, Godet T, Tiano M (2007) Acridine and acridone derivatives, anticancer properties and synthetic methods: where are we now? Anticancer Agents Med Chem 7:139-169 (Pubitemid 46403582)
28. Desbois N, Gardette M, Papon J, Labarre P, Maisonial A, Auzeloux P, Lartigue C, Bouchon B, Debiton E, Blache Y et al (2008) Design, synthesis and preliminary biological evaluation of acridine compounds as potential agents for a combined targeted chemo-radionuclide therapy approach to melanoma. Bioorg Med Chem 16:7671-7690
29. Bielawski K, Winnicka K, Bielawska A (2006) Inhibition of DNA topoisomerases I and II, and growth inhibition of breast cancer MCF-7 cells by ouabain, digoxin and proscillaridin A. Biol Pharm Bull 29:1493-1497
30. Peixoto P, Zeghida W, Carrez D, Wu TD, Wattez N, Croisy A, Demeunynck M, Guerquin-Kern JL, Lansiaux A (2009) Unusual cellular uptake of cytotoxic 4-hydroxymethyl-3-aminoacridine. Eur J Med Chem 44:4758-4763
31. Wolf M, Bauder-Wust U, Eskerski H, Bauer C, Eisenhut M (2007) Role of acidic cell organelles in the higher nonmelanoma retention of melanoma markers based on N-(2-dialkylaminoethyl) benzamides and the cytotoxicity of alkylating benzamides. Melanoma Res 17:61-73 (Pubitemid 46673899)
32. Finlay GJ, Riou JF, Baguley BC (1996) From amsacrine to DACA (N-[2-(dimethylamino) ethyl]acridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives. Eur J Cancer 32 A: 708-714
33. Rapp M, Maurizis JC, Papon J, Labarre P, Wu TD, Croisy A, Guerquin-Kern JL, Madelmont JC, Mounetou E (2008) A new O6-alkylguanine-DNA alkyltransferase inhibitor associated with a nitrosourea (cystemustine) validates a strategy of melanoma-targeted therapy in murine B16 and humanresistant M4Beu melanoma xenograft models. J Pharmacol Exp Ther 326:171-177 (Pubitemid 351872125)
34. Baguley BC, Denny WA, Atwell GJ, Cain BF (1981) Potential antitumor agents. 34. Quantitative relationships between DNA binding and molecular structure for 9-anilinoacridines substituted in the anilino ring. J Med Chem 24:170-177 (Pubitemid 11183408)
35. Labarre P, Papon J, Rose AH, Guerquin-Kern JL, Morandeau L, Wu TD, Moreau MF, Bayle M, Chezal JM, Croisy A et al (2008) Melanoma affinity in mice and immunosuppressed sheep of [(125) I]N-(4-dipropylaminobutyl)-4-iodobenzamide, a new targeting agent. Nucl Med Biol 35:783-791
36. Urashima T, Nagasawa H, Wang K, Adelstein SJ, Little JB, Kassis AI (2006) Induction of apoptosis in human tumor cells after exposure to Auger electrons: comparison with gamma-ray exposure. Nucl Med Biol 33:1055-1063 (Pubitemid 44791956)
37. Labarre P, Papon J, Moreau MF, Moins N, Bayle M, Veyre A, Madelmont JC (2002) Melanin affinity of N-(2-diethylaminoethyl) - 4-iodobenzamide, an effective melanoma imaging agent. Melanoma Res 12:115-121 (Pubitemid 34478451)
38. Chen KG, Valencia JC, Lai B, Zhang G, Paterson JK, Rouzaud F, Berens W, Wincovitch SM, Garfield SH, Leapman RD et al (2006) Melanosomal sequestration of cytotoxic drugs contributes to the intractability of malignant melanomas. Proc Natl Acad Sci USA 103:9903-9907 (Pubitemid 43993595)
39. Boyd M, Ross SC, Dorrens J, Fullerton NE, Tan KW, Zalutsky MR, Mairs RJ (2006) Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with alpha-, beta-, and auger electron-emitting radionuclides. J Nucl Med 47:1007-1015 (Pubitemid 46939954)
40. Benderitter M, Vincent-Genod L, Pouget JP, Voisin P (2003) The cell membrane as a biosensor of oxidative stress induced by radiation exposure: a multiparameter investigation. Radiat Res 159:471-483 (Pubitemid 36397769)
41. Michel RB, Brechbiel MW, Mattes MJ (2003) A comparison of 4 radionuclides conjugated to antibodies for single-cell kill. J Nucl Med 44:632-640 (Pubitemid 39663432)
42. Pouget JP, Santoro L, Raymond L, Chouin N, Bardies M, Bascoul-Mollevi C, Huguet H, Azria D, Kotzki PO, Pelegrin M et al (2008) Cell membrane is a more sensitive target than cytoplasm to dense ionization produced by auger electrons. Radiat Res 170:192-200
43. Santoro L, Boutaleb S, Garambois V, Bascoul-Mollevi C, Boudousq V, Kotzki PO, Pelegrin M, Navarro-Teulon I, Pelegrin A, Pouget JP (2009) Noninternalizing monoclonal antibodies are suitable candidates for 125I radioimmunotherapy of small-volume peritoneal carcinomatosis. J Nucl Med 50:2033-2041
44. Moins N, Papon J, Seguin H, Gardette D, Moreau MF, Labarre P, Bayle M, Michelot J, Gramain JC, Madelmont JC et al (2001) Synthesis, characterization and comparative biodistribution study of a new series of p-iodine-125 benzamides as potential melanoma imaging agents. Nucl Med Biol 28:799-808 (Pubitemid 32900638)